<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03797937</url>
  </required_header>
  <id_info>
    <org_study_id>2018BDM2</org_study_id>
    <nct_id>NCT03797937</nct_id>
  </id_info>
  <brief_title>Microbiome Benchmarking to Identify Perturbations in Multiple Sclerosis II</brief_title>
  <official_title>Microbiome Benchmarking to Identify Perturbations in Multiple Sclerosis II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National MS Center Melsbroek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National MS Center Melsbroek</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this longitudinal study is to explore the association between the gut microbiota
      and inflammatory disease activity in early onset multiple sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using metagenomics, as well as clinical, immunological, and radiological observations, the
      investigators will investigate if active relapsing-remitting multiple sclerosis patients have
      a more pro-inflammatory gut microbiota signature than multiple sclerosis patients with less
      active disease and matched healthy controls.

      More specifically, the investigators will investigate whether temporal variability of the gut
      microbiota is related to inflammatory disease activity in multiple sclerosis, whether changes
      in the gut microbiota are predictive of future inflammatory disease activity in multiple
      sclerosis, and whether gut microbiota characteristics are predictive of the disease course
      after 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical evidence for active disease</measure>
    <time_frame>3 years</time_frame>
    <description>Time to first relapse (after baseline) will be reported for all patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiological evidence for active disease</measure>
    <time_frame>3 years</time_frame>
    <description>Occurrence of new contrast-enhancing T1 hyper intense lesions, or changes in white matter lesion volume (i.e. new or enlarging T2 hyper intense lesions)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Multiple sclerosis (MS) patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo magnetic resonance imaging (MRI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched healthy controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic resonance imaging (MRI)</intervention_name>
    <description>MRI scanner</description>
    <arm_group_label>Multiple sclerosis (MS) patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of MS (as defined by the 2010 McDonald criteria).

          -  Occurrence of symptoms no longer than 5 years before baseline.

          -  Aged 18-55.

          -  Willingness to participate in the study and to sign the informed consent.

        Exclusion Criteria:

          -  Current treatment with monoclonal antibodies (Tysabri, Lemtrada, Zinbryta, or
             Ocrevus).

          -  Treatment with high doses of systemic steroids 2 months before baseline.

          -  Use of antibiotics 3 months before baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ann Van Remoortel</last_name>
    <phone>32-2-5978724</phone>
    <email>ann.vanremoortel@mscenter.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brussel</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annick Van Merhaegen</last_name>
      <phone>024763435</phone>
      <email>annick.vanmerhaegenwieleman@uzbrussel.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationaal Multiple Sclerose Centrum Melsbroek</name>
      <address>
        <city>Melsbroek</city>
        <state>Vlaams-Brabant</state>
        <zip>1820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Van Remoortel</last_name>
      <phone>025978724</phone>
      <email>ann.vanremoortel@mscenter.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2019</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National MS Center Melsbroek</investigator_affiliation>
    <investigator_full_name>Marie D'hooghe</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

